ACCM Meeting Statement – Meeting 38, 6 November 2025
23 Jan 2026
Role of the ACCM in TGA decision-making
The Advisory Committee on Complementary Medicines (ACCM) is a statutory advisory body established under the Therapeutic Goods Regulations 1990. It is one of seven statutory advisory committees that provide the Therapeutic Goods Administration (TGA) with independent expert advice on scientific and technical matters to support regulatory decisions and other processes.
The ACCM advises the TGA on matters including the inclusion, variation, or retention of complementary medicines on the Australian Register of Therapeutic Goods (ARTG). While this advice is an important part of the TGA’s regulatory process, it is only one element considered by TGA delegates, who are not required to follow the committee’s recommendations.
It is also important to note that information about the ACCM’s advice may not be publicly available immediately after a meeting. Meeting statements like this one aim to provide a general overview of matters considered as soon as reasonably possible.
Overview of matters considered
At Meeting 38, the ACCM was asked to provide advice on two main matters:
- Vitamin list and advertising rules – Menaquinone-7
- The TGA reviewed advertising rules for additional substances and vitamin names in the Therapeutic Goods Regulations 1990.
- The ACCM advised on the classification of menaquinone-7 to ensure clarity for consumers and reviewed labelling statements to reflect current scientific data.
- Safety review of Myristica fragrans (nutmeg/mace)
- An updated review was initiated due to concerns about compounds in nutmeg/mace with abortifacient activity.
- The committee assessed whether existing regulatory settings adequately protect pregnant and breastfeeding women and whether stronger measures, such as contraindication warnings, are needed.
The advice provided by the ACCM will now be considered as part of the TGA’s regulatory decision-making process.
Further information
Meeting statements are made publicly available after each session.
Source: Therapeutic Goods Administration (TGA), Advisory Committee on Complementary Medicines (ACCM)
